NextPlat shares surge 15.99% premarket on expected 75% sequential growth in 340B contract revenue from new business initiatives and expanded development efforts.

NextPlat Corp (NASDAQ: NXPL) rose 16.0% in premarket trading following reports of a 75% sequential quarterly growth in 340B contract revenue for Q4 2025, driven by new business initiatives implemented in the second half of 2025. The company attributed the growth to over 12,000 additional 340B and contracted prescriptions, with Chairman Rodney Barreto’s expanded role in business development securing two healthcare contracts earlier in 2025. NextPlat also highlighted strategic efforts to expand pharmacy services via joint ventures and acquisitions, reinforcing optimism about its healthcare segment’s momentum. These developments align with management’s focus on operational streamlining and customer engagement, positioning the stock for potential long-term growth despite a Q3 revenue decline.